Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.54 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705882 | 1.00 | DDB1 (0.54) | DDB1CRBNACKR3KDM1AIRAK1 | |
| SCHEMBL30706246 | 0.90 | DDB1 (0.55) | DDB1CRBNACKR3KDM1AIRAK1 | |
| SCHEMBL30706186 | 0.90 | DDB1 (0.55) | DDB1CRBNACKR3KDM1AIRAK1 | |
| SCHEMBL31232829 | 0.90 | DDB1 (0.57) | DDB1CRBN | |
| SCHEMBL30705954 | 0.85 | DDB1 (0.51) | DDB1CRBNKDM1A | |
| SCHEMBL30706101 | 0.85 | DDB1 (0.51) | DDB1CRBNKDM1A | |
| SCHEMBL30706233 | 0.84 | DDB1 (0.56) | DDB1CRBN | |
| SCHEMBL30706148 | 0.81 | DDB1 (0.70) | DDB1CRBNACKR3KDM1AIRAK1 | |
| SCHEMBL30705914 | 0.81 | DDB1 (0.70) | DDB1CRBNACKR3KDM1AIRAK1 | |
| SCHEMBL30706057 | 0.79 | DDB1 (0.52) | DDB1CRBNACKR3KDM1AIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | DDB1 141/4885CRBN 756/4885ACKR3 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.